FDMT

SEC source: 0001193125-26-006809 · ownership.xml · derivative · entry 1

SBLENDORIO GLENN · CIK 0001277478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-01-04

F1 · derivative.exercise_date: One-third of the shares subject to the option vest on the first anniversary measured from January 5 2026 (the "Vesting Commencement Date"), and 1/36th of the total number of shares vest in twenty-four (24) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.

SEC source: 0001193125-25-331299 · ownership.xml · derivative · entry 6

Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,308

Underlying: Common Stock · 220 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis.

F4 · derivative.exercise_date: The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.

F4 · derivative.expiration_date: The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.

SEC source: 0001193125-25-331299 · ownership.xml · derivative · entry 5

Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,984

Underlying: Common Stock · 866 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted Stock Units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.

F3 · derivative.expiration_date: The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.

SEC source: 0001193125-25-331299 · ownership.xml · nonDerivative · entry 4

Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,359

F2 · kind: The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001193125-25-331299 · ownership.xml · nonDerivative · entry 3

Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,438

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis.

SEC source: 0001193125-25-331299 · ownership.xml · nonDerivative · entry 2

Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,218

F2 · kind: The transaction represents an automatic sale to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001193125-25-331299 · ownership.xml · nonDerivative · entry 1

Gupta Ashoo · CIK 0002091461 · VP, Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,528

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted Stock Units convert into common stock on a one-for-one basis.

SEC source: 0001193125-25-326851 · ownership.xml · derivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,595

Underlying: Common Stock · 1,635 shares

Expires 2035-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0001193125-25-326851 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,594

SEC source: 0001193125-25-326851 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,229

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-320992 · ownership.xml · derivative · entry 2

THEUER CHARLES · CIK 0001631338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,333 shares

Expires 2026-03-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Fully vested.

SEC source: 0001193125-25-320992 · ownership.xml · nonDerivative · entry 1

THEUER CHARLES · CIK 0001631338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,684

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-315989 · ownership.xml · derivative · entry 1

Humer Kristian · CIK 0001872280 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 480,000

Underlying: Common Stock · 480,000 shares

Expires 2035-12-08

F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0001193125-25-288632 · ownership.xml · derivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,230

Underlying: Common Stock · 1,635 shares

Expires 2035-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0001193125-25-288632 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,594

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

SEC source: 0001193125-25-288632 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,229

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

SEC source: 0001193125-25-251874 · ownership.xml · derivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,295

Underlying: Common Stock · 1,084 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0001193125-25-251874 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,594

SEC source: 0001193125-25-251874 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,272

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-243946 · ownership.xml · derivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,865

Underlying: Common Stock · 1,635 shares

Expires 2035-03-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0001193125-25-243946 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,188

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

SEC source: 0001193125-25-243946 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,823

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

SEC source: 0001193125-25-238995 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,188

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

SEC source: 0001193125-25-221028 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,596

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.

F2 · balance_after: Reflects 3,222 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.

SEC source: 0000950170-25-088497 · ownership.xml · derivative · entry 1

Chacko Jacob · CIK 0001608936 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2035-06-16

F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0000950170-25-088484 · ownership.xml · derivative · entry 1

MILLIGAN JOHN F · CIK 0001191589 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,750

Underlying: Common Stock · 33,750 shares

Expires 2035-06-16

F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0000950170-25-088489 · ownership.xml · derivative · entry 1

Tomasello Shawn · CIK 0001617239 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2035-06-16

F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0000950170-25-088487 · ownership.xml · derivative · entry 1

THEUER CHARLES · CIK 0001631338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2035-06-16

F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0000950170-25-088496 · ownership.xml · derivative · entry 1

GRAY SUSANNAH · CIK 0001833453 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2035-06-16

F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0000950170-25-088486 · ownership.xml · derivative · entry 1

Miller-Rich Nancy · CIK 0001735084 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2035-06-16

F1 · kind: Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

SEC source: 0000950170-25-036696 · ownership.xml · derivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,500

Underlying: Common Stock · 78,500 shares

Expires 2035-03-05

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0000950170-25-036685 · ownership.xml · derivative · entry 1

Mehra Uneek · CIK 0001881504 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2035-03-05

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0000950170-25-036686 · ownership.xml · derivative · entry 1

Kim Robert Young · CIK 0001971608 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,300

Underlying: Common Stock · 92,300 shares

Expires 2035-03-05

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0000950170-25-036688 · ownership.xml · derivative · entry 1

Kirn David · CIK 0001834021 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 267,500

Underlying: Common Stock · 267,500 shares

Expires 2035-03-05

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0000950170-25-036683 · ownership.xml · derivative · entry 1

Kamal Fariborz · CIK 0001834020 · President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,400

Underlying: Common Stock · 178,400 shares

Expires 2035-03-05

F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0001415889-24-028837 · form4-12102024_091224.xml · derivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 3,610,000

Underlying: Common Stock · 535,000 shares

Expires not disclosed

F1 · kind: On December 9, 2024, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 535,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 535,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share.

F1 · price: On December 9, 2024, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 535,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 535,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share.

F4 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F4 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, the Reporting Persons shall not be entitled to exercise the Pre-Funded Warrant if it would cause the aggregate number of shares of Common Stock beneficially owned by the Reporting Persons, their affiliates and any persons who are members of a Section 13(d) group with the Reporting Persons or their affiliates to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2 · ownership.nature: Held directly by the Fund.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001415889-24-028837 · form4-12102024_091224.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 4,563,211

F1 · kind: On December 9, 2024, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 535,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 535,000 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share.

F2 · ownership.nature: Held directly by the Fund.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

SEC source: 0000921895-24-002631 · form407422010_11132024.xml · derivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Common Stock, $0.0001 par value · 240,000 shares

Expires not disclosed

F2 · kind: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F2 · price: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F6 · derivative.exercise_date: Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise.

F6 · derivative.expiration_date: Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise.

F1 · derivative.underlying: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-24-002631 · form407422010_11132024.xml · derivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,378,000

Underlying: Common Stock, $0.0001 par value · 2,378,000 shares

Expires not disclosed

F2 · kind: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F2 · price: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F6 · derivative.exercise_date: Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise.

F6 · derivative.expiration_date: Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise.

F1 · derivative.underlying: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-24-002631 · form407422010_11132024.xml · derivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,062,000

Underlying: Common Stock, $0.0001 par value · 3,062,000 shares

Expires not disclosed

F2 · kind: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F2 · price: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F6 · derivative.exercise_date: Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise.

F6 · derivative.expiration_date: Each Pre-Funded Warrant may be exercised for one share of common stock. The Pre-Funded Warrants are exercisable at any time and do not expire. A holder of Pre-Funded Warrants may not exercise such Pre-Funded Warrants if, after giving effect or immediately prior to to such exercise, such holder, its Attribution Parties (as defined in the Warrant To Purchase Shares of Common Stock) and any other persons whose beneficial ownership of shares of common stock would be aggregated with such holder's for purposes of Section 13(d) of the Exchange Act, would beneficially own (i) in excess of 9.99% of the total number of issued and outstanding shares of common stock, or (ii) securities representing voting power in excess of 9.99% of the combined voting power of all of the securities of the Issuer then outstanding, in each case, following such exercise.

F1 · derivative.underlying: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000921895-24-002631 · form407422010_11132024.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,911

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · kind: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F2 · price: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F5 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-24-002631 · form407422010_11132024.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 662,970

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · kind: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F2 · price: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F4 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-24-002631 · form407422010_11132024.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 830,237

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a group for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Exchange Act") that previously collectively beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · kind: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F2 · price: On November 8, 2024, certain of the Reporting Persons entered into an Exchange Agreement with the Issuer (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 5,775,000 shares of common stock of the Issuer for a total of 5,775,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 3,062,000 shares for 3,062,000 Pre-Funded Warrants, BVF2 exchanged 2,378,000 shares for 2,378,000 Pre-Funded Warrants and Trading Fund OS exchanged 240,000 shares for 240,000 Pre-Funded Warrants.

F3 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000950170-24-107903 · ownership.xml · derivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,379

Underlying: Common Stock · 500 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0000950170-24-107903 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,781

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

SEC source: 0000950170-24-107903 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,281

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

SEC source: 0000950170-24-099505 · ownership.xml · derivative · entry 3

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,879

Underlying: Common Stock · 500 shares

Expires 2032-06-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.

SEC source: 0000950170-24-099505 · ownership.xml · nonDerivative · entry 2

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,781

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

SEC source: 0000950170-24-099505 · ownership.xml · nonDerivative · entry 1

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,281

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

SEC source: 0000950170-24-084725 · ownership.xml · derivative · entry 5

Bizily Scott · CIK 0001920738 · Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,502

Underlying: Common Stock · 1,250 shares

Expires 2032-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023.

F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.